Peripheral nerve repair is entering a new phase of clinical recognition, and Axogen Inc. (AXGN) is positioned at the center of that shift. With growing support from surgical societies and expanding payer coverage, the company's biologic platform is gaining traction.
At the heart of its strategy is Avance Nerve Graft, a product now approaching a critical regulatory milestone that could reshape its commercial trajectory.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.